PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel ...

Moderna announced Wednesday that the Trump administration has canceled a major contract worth nearly $700 million for the ...

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

PharmAla Biotech (CSE:MDMA) issued a public warning after discovering that unknown parties are illegally marketing a nasal ...

PharmAla says its LaNeo MDMA drug products are exclusively available through a qualified practitioner’s prescription and ...

Canada], May 29: Mapmygenome, an AI-driven leader in genomics and personalized health, announced the strategic acquisition of ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...

Strive Asset Management and Asset Entities (Nasdaq: ASST) today announced the signing of a $750 million private investment in ...